NORD is deeply concerned about the “Promising Pathway Act” recently introduced in both the Senate and the House. Contrary to the stated goal of giving patients with serious and life-threatening diseases a “chance at receiving meaningful treatments,” this legislation, by its own terms, would lower FDA’s approval standards, exposing patients to unsafe and ineffective medicines. Rare disease patients deserve access to innovative, safe, and effective medicines. Just as we have since we fought for the enactment of the 1983 Orphan Drug Act, NORD will continue to advocate for productive ways to fulfill this goal. In keeping with NORD’s mission to promote the best interests of the rare disease community, we will fight to ensure this bill does not become law.
NORD Issues Statement on Recently Introduced “Promising Pathway Act”
Categorized in -
